公开(公告)号：US11045448B2

公开(公告)日：2021-06-29

申请号：US16497856

申请日：2018-03-30

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Shilin Xu ,  Liyue Huang ,  Jeanne Stuckey ,  Tianfeng Xu

IPC: A61K31/397 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/5377 ,  C07D205/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20200022953A1

公开(公告)日：2020-01-23

申请号：US16497856

申请日：2018-03-30

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Shilin Xu ,  Liyue Huang ,  Jeanne Stuckey ,  Tianfeng Xu

IPC: A61K31/397 ,  C07D401/14 ,  C07D401/06 ,  C07D413/14 ,  C07D401/12 ,  C07D205/04 ,  A61K31/4523 ,  A61K31/4709 ,  A61K31/454 ,  A61K31/5377

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20190152947A1

公开(公告)日：2019-05-23

申请号：US16098147

申请日：2017-05-02

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34

Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20210198237A1

公开(公告)日：2021-07-01

申请号：US17101323

申请日：2020-11-23

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US10899738B2

公开(公告)日：2021-01-26

申请号：US16098147

申请日：2017-05-02

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34 ,  A61P35/00

Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.